Individualized Screening Interval for Prostate Cancer Based on Prostate-Specific Antigen Level
- 12 September 2005
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Internal Medicine
- Vol. 165 (16), 1857-1861
- https://doi.org/10.1001/archinte.165.16.1857
Abstract
Prostate cancer is an important and growing health problem particularly facing men in the Western world. There were about 540 000 new cases worldwide in 2000. Nearly 300 000 of these cases were diagnosed in western Europe or North America.1Keywords
This publication has 15 references indexed in Scilit:
- Faculty Opinions recommendation of The influence of finasteride on the development of prostate cancer.Published by H1 Connect ,2015
- Results of a randomized, population‐based study of biennial screening using serum prostate‐specific antigen measurement to detect prostate carcinomaCancer, 2004
- Possibility of re‐screening intervals of more than one year in men with PSA levels of 4.0 ng/ml or lessThe Prostate, 2003
- The Influence of Finasteride on the Development of Prostate CancerThe New England Journal of Medicine, 2003
- Screening for prostate cancerUrologic Clinics of North America, 2003
- Diagnostic significance of digital rectal examination and transrectal ultrasonography in men with prostate-specific antigen levels of 4 ng/mL or lessUrology, 2001
- Rationale for earlier and less frequent prostate cancer screeningUrology, 2001
- Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0-3.9 ng/ml)The Prostate, 2001
- Outcome of Laterally Directed Sextant Biopsies of the Prostate in Screened Males Aged 50–66 YearsEuropean Urology, 2001
- The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancerUrology, 1997